125Ⅰ prevents local cancer recurrence after hepatectomy
- VernacularTitle:肝癌切除术后残肝断面125Ⅰ粒子植入预防肝癌复发
- Author:
Kaiyun CHEN
;
Guoan XIANG
;
Hanning WANG
;
Fanglian XIAO
- Publication Type:Journal Article
- Keywords:
Carcinoma,hepatocellular;
Neoplasms recurrence,local;
Hepatectomy;
Iodine-125
- From:
Chinese Journal of General Surgery
2008;23(12):932-934
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effectiveness of residue liver embedding of iodine-125 on recurrence after hepatectomy in hepatocellular carcinoma patients. Methods In this study, 85 cases with resectable hepatocellular carcinoma were collected and divided into two groups randomly: intrahepatic embedding of iodine-125 group and control group. The serum values of T lymphocyte phenotypes (CD3 + CD4 + ,CD8 +), NK cells,TB IL, ALT, AST, AFP and MMP-9 were measured in all patients 1 day before and 7, 30 days after the operation respectively; B ultrasonic and CT were used to detect for intrahepatic dissemination and recurrence of HCC after hepateetomy. All patients were followed-up from 16 to 55 months (average 35.4 months). Results Surgery were successful in all cases. There were no difference in T lymphocyte phenotypes, NK cells, TBIL, ALT and AST between the two groups (P＞0.05). The serum values of AFP and MMP-9 were much lower in the intrahepatic embedding of iodine-125 group than the control group(P<0.05). In iodine-125 embedding group, the 0.5-, 1-year recurrent rates were 2.3%、6.9%, respectively, compared with 14.2% and 26.1%, respectively, in control group (all P<0.05). Conclusions Intrahepatic embedding of iodine-125 in HCC patients after hepatectomy decreases values of AFP, MMP-9 and local cancer recurrence rate in HCC patients after hepatectomy.
